Jun 03, 2025
BioVaxys Issues Corporate Update
May 29, 2025
BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
May 07, 2025
BioVaxys and Sona Nanotech Enter Research Collaboration
Apr 22, 2025
BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture
Jan 16, 2025
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
Jan 14, 2025
BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025
Dec 17, 2024
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up
Nov 20, 2024
BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY
Nov 05, 2024
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium
Oct 31, 2024
BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems
Oct 28, 2024
BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024
Oct 08, 2024
BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor
Sep 12, 2024
BioVaxys to Present at the Life Sciences Investor Forum on September 19th
Sep 04, 2024
BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit
Aug 22, 2024
BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases
Aug 19, 2024
SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN
Jul 29, 2024
Biovaxys Signs Binding Letter of Intent to Develop DPX(TM)-Based Vaccines for Life Threatening Food Allergies
Jul 23, 2024
BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE
Jul 18, 2024
Brittany Davison, CPA, CA, Joins BioVaxys as Business Advisor
Jul 17, 2024
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF TRIAL TO TEST IMMUNOCONTRACEPTION IN ASIAN ELEPHANTS